Search

Your search keyword '"Tarasco, M"' showing total 6 results
Start Over Author "Tarasco, M" Publication Type Electronic Resources
6 results on '"Tarasco, M"'

1. Non-Coding RNAs in Myasthenia Gravis: From Immune Regulation to Personalized Medicine

Author

Iacomino, N, Tarasco, M, Berni, A, Ronchi, J, Mantegazza, R, Cavalcante, P, Foti, M, Tarasco, Maria Cristina, Berni, Alessia, Ronchi, Jacopo, Mantegazza, Renato, Cavalcante, Paola, Foti, Maria., Iacomino, N, Tarasco, M, Berni, A, Ronchi, J, Mantegazza, R, Cavalcante, P, Foti, M, Tarasco, Maria Cristina, Berni, Alessia, Ronchi, Jacopo, Mantegazza, Renato, Cavalcante, Paola, and Foti, Maria.

Abstract

Myasthenia gravis (MG) is an antibody-mediated autoimmune disorder characterized by altered neuromuscular transmission, which causes weakness and fatigability in the skeletal muscles. The etiology of MG is complex, being associated with multiple genetic and environmental factors. Over recent years, progress has been made in understanding the immunological alterations implicated in the disease, but the exact pathogenesis still needs to be elucidated. A pathogenic interplay between innate immunity and autoimmunity contributes to the intra-thymic MG development. Epigenetic changes are critically involved in both innate and adaptive immune response regulation. They can act as (i) pathological factors besides genetic predisposition and (ii) co-factors contributing to disease phenotypes or patient-specific disease course/outcomes. This article reviews the role of non-coding RNAs (ncRNAs) as epigenetic factors implicated in MG. Particular attention is dedicated to microRNAs (miRNAs), whose expression is altered in MG patients’ thymuses and circulating blood. The long ncRNA (lncRNA) contribution to MG, although not fully characterized yet, is also discussed. By summarizing the most recent and fast-growing findings on ncRNAs in MG, we highlight the therapeutic potential of these molecules for achieving immune regulation and their value as biomarkers for the development of personalized medicine approaches to improve disease care.

Published
2024

2. Whole miRNome profiling in myasthenia gravis thymus: novel insights into the molecular events underlying autoimmunity

Author

Tarasco, M, Iacomino, N, Scandiffio, L, Bortone, F, Marcuzzo, S, Bonanno, S, Frangiamore, R, Pistillo, D, Voulaz, E, Alloisio, M, Maggi, L, Antozzi, C, Mantegazza, R, Cavalcante, P, Maria Cristina Tarasco, Nicola Iacomino, Letizia Scandiffio, Federica Bortone, Stefania Marcuzzo, Silvia Bonanno, Rita Frangiamore, Daniela Pistillo, Emanuele Voulaz, Marco Alloisio, Lorenzo Maggi, Carlo Antozzi, Renato Mantegazza, Paola Cavalcante, Tarasco, M, Iacomino, N, Scandiffio, L, Bortone, F, Marcuzzo, S, Bonanno, S, Frangiamore, R, Pistillo, D, Voulaz, E, Alloisio, M, Maggi, L, Antozzi, C, Mantegazza, R, Cavalcante, P, Maria Cristina Tarasco, Nicola Iacomino, Letizia Scandiffio, Federica Bortone, Stefania Marcuzzo, Silvia Bonanno, Rita Frangiamore, Daniela Pistillo, Emanuele Voulaz, Marco Alloisio, Lorenzo Maggi, Carlo Antozzi, Renato Mantegazza, and Paola Cavalcante

Published
2023

3. Whole miRNome sequencing in myasthenia gravis thymus reveals dysregulated miRNA/target gene networks implicated in autoimmunity

Author

Tarasco, M, Iacomino, N, Scandiffio, L, Bortone, F, Marcuzzo, S, Bonanno, S, Frangiamore, R, Pistillo, D, Voulaz, E, Alloisio, M, Maggi, L, Antozzi, C, Mantegazza, R, Cavalcante., A, Maria Cristina Tarasco, Nicola Iacomino, Letizia Scandiffio, Federica Bortone, Stefania Marcuzzo, Silvia Bonanno, Rita Frangiamore, Daniela Pistillo, Emanuele Voulaz, Marco Alloisio, Lorenzo Maggi, Carlo Antozzi, Renato Mantegazza, and Paola Cavalcante., Tarasco, M, Iacomino, N, Scandiffio, L, Bortone, F, Marcuzzo, S, Bonanno, S, Frangiamore, R, Pistillo, D, Voulaz, E, Alloisio, M, Maggi, L, Antozzi, C, Mantegazza, R, Cavalcante., A, Maria Cristina Tarasco, Nicola Iacomino, Letizia Scandiffio, Federica Bortone, Stefania Marcuzzo, Silvia Bonanno, Rita Frangiamore, Daniela Pistillo, Emanuele Voulaz, Marco Alloisio, Lorenzo Maggi, Carlo Antozzi, Renato Mantegazza, and and Paola Cavalcante.

Published
2023

4. Whole miRNome sequencing in myasthenia gravis thymus reveals dysregulated miRNA/target gene networks implicated in autoimmunity

Author

Tarasco, M, Iacomino, N, Scandiffio, L, Bortone, F, Marcuzzo, S, Bonanno, S, Frangiamore, R, Pistillo, D, Voulaz, E, Alloisio, M, Maggi, L, Antozzi, C, Mantegazza, R, Cavalcante., A, Maria Cristina Tarasco, Nicola Iacomino, Letizia Scandiffio, Federica Bortone, Stefania Marcuzzo, Silvia Bonanno, Rita Frangiamore, Daniela Pistillo, Emanuele Voulaz, Marco Alloisio, Lorenzo Maggi, Carlo Antozzi, Renato Mantegazza, and Paola Cavalcante., Tarasco, M, Iacomino, N, Scandiffio, L, Bortone, F, Marcuzzo, S, Bonanno, S, Frangiamore, R, Pistillo, D, Voulaz, E, Alloisio, M, Maggi, L, Antozzi, C, Mantegazza, R, Cavalcante., A, Maria Cristina Tarasco, Nicola Iacomino, Letizia Scandiffio, Federica Bortone, Stefania Marcuzzo, Silvia Bonanno, Rita Frangiamore, Daniela Pistillo, Emanuele Voulaz, Marco Alloisio, Lorenzo Maggi, Carlo Antozzi, Renato Mantegazza, and and Paola Cavalcante.

Published
2023

5. MicroRNA quali biomarcatori di risposta alle terapie immunosoppressive nella miastenia gravis: prospettive per una medicina personalizzata

Author

Tarasco, M, Iacomino, N, Ballardini, M, Frangiamore, R, Vanoli, F, Antozzi, C, Foti, M, Mantegazza, R, Cavalcante, P, Maria Cristina Tarasco, Nicola Iacomino, Marta Ballardini, Rita Frangiamore, Fiammetta Vanoli, Carlo Antozzi, Maria Foti, Renato Mantegazza, Paola Cavalcante, Tarasco, M, Iacomino, N, Ballardini, M, Frangiamore, R, Vanoli, F, Antozzi, C, Foti, M, Mantegazza, R, Cavalcante, P, Maria Cristina Tarasco, Nicola Iacomino, Marta Ballardini, Rita Frangiamore, Fiammetta Vanoli, Carlo Antozzi, Maria Foti, Renato Mantegazza, and Paola Cavalcante

Published
2022

6. ABO blood group A transferase and its codon 69 substitution enzymes synthesize FORS1 antigen of FORS blood group system

Author

Yamamoto, M, Tarasco, M, Cid, E, Kobayashi, H, Yamamoto, F, Yamamoto M., Tarasco M. C., Cid E., Kobayashi H., Yamamoto F., Yamamoto, M, Tarasco, M, Cid, E, Kobayashi, H, Yamamoto, F, Yamamoto M., Tarasco M. C., Cid E., Kobayashi H., and Yamamoto F.

Abstract

Human histo-blood group A transferase (AT) catalyzes the biosynthesis of oligosaccharide A antigen important in blood transfusion and cell/tissue/organ transplantation. This enzyme may synthesize Forssman antigen (FORS1) of the FORS blood group system when exon 3 or 4 of the AT mRNA is deleted and/or the LeuGlyGly tripeptide at codons 266-268 of AT is replaced by GlyGlyAla. The Met69Ser/Thr substitutions also confer weak Forssman glycolipid synthase (FS) activity. In this study, we prepared the human AT derivative constructs containing any of the 20 amino acids at codon 69 with and without the GlyGlyAla substitution, transfected DNA to newly generated COS1(B3GALNT1+A4GALT) cells expressing an enhanced level of globoside (Gb4), the FS acceptor substrate, and immunologically examined the FORS1 expression. Our results showed that all those substitution constructs at codon 69 exhibited FS activity. The combination with GlyGlyAla significantly increased the activity. The conserved methionine residue in the ABO, but not GBGT1, gene-encoded proteins may implicate its contribution to the separation of these genes in genetic evolution. Surprisingly, with increased Gb4 availability, the original human AT with the methionine residue at codon 69 was also demonstrated to synthesize FORS1, providing another molecular mechanism of FORS1 appearance in cancer of ordinary FORS1-negative individuals.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results